Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis

A Tiwari, K Tashiro, A Dixit, A Soni, K Vogel, B Hall… - Gastroenterology, 2020 - Elsevier
Background & Aims Pancreatic ductal adenocarcinomas (PDACs) are hypovascular,
resulting in the up-regulation of hypoxia inducible factor 1 alpha (HIF1A), which promotes the …

Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre …

…, T Karashima, K Masui, F Fukuta, K Tashiro… - Cancer Immunology …, 2022 - Springer
Neutrophil-to-lymphocyte ratio (NLR) was reported to be associated with prognosis of urothelial
cancer (UC) patients receiving systemic chemotherapy or immunotherapy. However, it …

Impact of the objective response to and number of cycles of platinum‐based first‐line chemotherapy for metastatic urothelial carcinoma on overall survival of patients …

…, R Kurahashi, Y Ozaki, Y Tashiro… - … Journal of Urology, 2021 - Wiley Online Library
Objectives To investigate the impact of the number of cycles and objective response to
chemotherapy on overall survival in patients with metastatic urothelial carcinoma treated with …

[HTML][HTML] Risk factors for perioperative hemodynamic instability in pheochromocytoma: a systematic review and meta-analysis

…, K Iwatani, K Takahashi, K Ito, K Tashiro… - Journal of clinical …, 2021 - mdpi.com
Objective: To evaluate the risk factors of perioperative hemodynamic instability in
pheochromocytoma, we conducted a systematic search of the literature using the Preferred …

Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis

…, H Araki, R Kurahashi, Y Ozaki, Y Tashiro… - BJU …, 2022 - Wiley Online Library
Objectives To assess the impact of histological variants on survival and response to treatment
with pembrolizumab in patients with chemo‐resistant urothelial carcinoma (UC). Patients …

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer

M Shiota, D Takamatsu, T Kimura, K Tashiro… - Cancer …, 2022 - Wiley Online Library
The treatment for lymph node involvement (LNI) after radical prostatectomy (RP) has not
been established. This study aimed to reveal the outcomes of various management strategies …

Prognostication in lymph node-positive prostate cancer with no PSA persistence after radical prostatectomy

…, M Miyake, M Tsutsumi, Y Yamamoto, K Tashiro… - Annals of Surgical …, 2024 - Springer
Background This study aimed to create a prognostic model to predict disease recurrence
among patients with lymph node involvement but no prostate-specific antigen (PSA) …

The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and …

…, F Urabe, K Iwatani, H Suzuki, Y Imai, K Tashiro… - International Journal of …, 2023 - Springer
Background Although the optimal management of locally advanced prostate cancer (PCa)
remains unclear, local definitive therapy, thus combined radiotherapy and androgen …

Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy

…, F Urabe, K Iwatani, M Nakazono, K Tashiro… - International Journal of …, 2023 - Springer
Background Although brachytherapy is a standard treatment option for patients with high-risk
prostate cancer, only a few studies have compared low-dose-rate brachytherapy (LDR-BT) …

How long is long enough to secure disease control after low-dose-rate brachytherapy in combination with other modalities in intermediate-risk, localized prostate …

F Urabe, T Kimura, H Sasaki, K Tashiro… - International Journal of …, 2022 - Springer
Purpose Previous studies have demonstrated excellent overall outcomes in patients who
underwent low-dose-rate brachytherapy (LDR-BT) in intermediate-risk, localized prostate …